Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in
endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in
schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced
elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for
the binding of the radioligand. We hypothesize there will be greater increase in ACh level
(or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects.
We hypothesize there will be greater increase in ACh level (or greater reduction in radio
tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the
extent of this change will be different than in controls.
We are also measuring the sensitivity of PHNO binding to changes in dopamine levels in
healthy smoking and nonsmoking subjects before and after amphetamine challenge.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)